Dec 21 (Reuters) - Nuvo Research Inc NRI.TO :
* Research reports topline results of phase 2 trial of Wf10(TM) for the
treatment of allergic rhinitis
* Says study fails to demonstrate separation between wf10 and placebo
* Says company will discontinue development of wf10 and focus on other pipeline
products
* Says results are not sufficient to justify the further development of wf10
for the treatment of allergic rhinitis
* These results do not affect the company's previously announced plans to split
Nuvo into two separate, publicly traded companies
* Source text for Eikon ID:nCNWkrNLDa
* Further company coverage NRI.TO